黑料网

Neuroimmunology; Genetics; GWAS; Autoimmunity; Multiple Sclerosis; NMOSD; Autoimmune Encephalitis

Introduction

Neuroimmunological disorders result from aberrant immune responses targeting the nervous system, leading to inflammation, demyelination, and neuronal damage. These conditions, including MS, NMOSD, and various forms of autoimmune encephalitis, pose significant challenges for diagnosis and treatment. A substantial body of evidence indicates a strong genetic component in the susceptibility to these disorders. While environmental factors play a role, genetic predisposition is crucial in determining an individual's risk. Understanding the genetic basis of neuroimmunological disorders is essential for elucidating disease mechanisms, identifying potential therapeutic targets, and developing personalized treatment strategies. This review provides an overview of the current state of knowledge regarding the genetic architecture of these complex disorders, focusing on insights gained from various genetic studies.

Genetic Studies in Neuroimmunological Disorders

Various genetic approaches have been employed to investigate the genetic basis of neuroimmunological disorders.

Candidate Gene Studies: Early genetic studies focused on candidate genes based on their known or suspected roles in immune function or nervous system development. These studies often investigated polymorphisms in genes encoding cytokines, chemokines, HLA molecules, and other immune-related proteins. While these studies identified some associations, their limited scope and the challenge of replicating findings across different populations highlighted the need for more comprehensive approaches.

Genome-Wide Association Studies (GWAS): GWAS revolutionized the field of complex disease genetics by scanning the entire genome for common genetic variants (single nucleotide polymorphisms or SNPs) associated with disease risk. GWAS in MS have identified numerous susceptibility loci, primarily within the HLA region and in genes involved in immune regulation and function [1]. These studies have provided strong evidence for the involvement of both innate and adaptive immune pathways in MS pathogenesis. For example, variants in IL2RA, IL7R, and CD58 have been consistently associated with MS risk, highlighting the importance of T cell activation and regulation. Similarly, GWAS in NMOSD have identified associations with HLA loci and genes involved in B cell function and complement activation [2].

Next-Generation Sequencing (NGS): NGS technologies, including whole-exome sequencing (WES) and whole-genome sequencing (WGS), allow for the comprehensive analysis of rare genetic variants, including single nucleotide variants (SNVs), insertions, and deletions. While GWAS primarily identify common variants with modest effect sizes, NGS can uncover rare variants with larger effects that may contribute to disease in specific individuals or families. Studies using NGS have identified rare variants in genes such as TYK2 and NR1H3 in MS, suggesting a role for these genes in disease susceptibility [3]. In autoimmune encephalitis, NGS has been instrumental in identifying genetic variants associated with specific autoantibody-mediated syndromes [4].

Epigenetic Studies: Epigenetic modifications, such as DNA methylation and histone modifications, can influence gene expression without altering the underlying DNA sequence. Studies investigating epigenetic changes in neuroimmunological disorders have revealed alterations in DNA methylation patterns and histone modifications in immune cells and brain tissue from affected individuals [5]. These epigenetic changes may contribute to disease pathogenesis by modulating the expression of genes involved in immune function and inflammation.

Gene-Environment Interactions: The development of neuroimmunological disorders is likely influenced by complex interactions between genetic predisposition and environmental factors. Studies investigating gene-environment interactions have identified several environmental risk factors for MS, including Epstein-Barr virus (EBV) infection, vitamin D deficiency, and smoking [6]. These environmental factors may interact with specific genetic variants to increase disease risk.

Genetic Architecture of Specific Neuroimmunological Disorders

Multiple Sclerosis (MS): MS has the most well-defined genetic architecture among neuroimmunological disorders. GWAS have identified over 200 susceptibility loci, explaining a substantial portion of the heritability of MS. The HLA region, particularly HLA-DRB1, shows the strongest association with MS risk. Other susceptibility genes are involved in T and B cell function, cytokine signaling, and innate immunity [7].

Neuromyelitis Optica Spectrum Disorder (NMOSD): NMOSD, characterized by autoantibodies targeting aquaporin-4 (AQP4), also has a genetic component. GWAS have identified associations with HLA loci and genes involved in B cell function and complement activation. Studies have also shown a genetic association with Fc receptor-like 3 (FCFRL3), a gene involved in B-cell regulation [8].

Autoimmune Encephalitis: Autoimmune encephalitis encompasses a diverse group of conditions characterized by inflammation of the brain parenchyma. The genetic basis of these disorders is less well understood compared to MS and NMOSD. However, studies have identified associations with HLA loci and genes involved in immune regulation. In specific forms of autoimmune encephalitis, such as those associated with antibodies against NMDA receptors or LGI1, genetic factors may contribute to disease susceptibility [9].

Implications for Diagnosis and Therapy

Understanding the genetic basis of neuroimmunological disorders has important implications for diagnosis and therapy. Genetic risk scores, based on the combined effects of multiple susceptibility variants, may be used to identify individuals at increased risk of developing these disorders. This could allow for earlier intervention and potentially prevent or delay disease onset. Furthermore, identifying specific genetic variants associated with disease subtypes or treatment response could facilitate personalized medicine approaches. For instance, pharmacogenomic studies could identify individuals who are more likely to respond to specific immunomodulatory therapies based on their genetic makeup. Moreover, understanding the genes and pathways involved in disease pathogenesis can lead to the development of novel therapeutic targets. For example, identifying specific cytokines or signaling molecules that are dysregulated in these disorders can guide the development of targeted therapies that block these pathways.

Challenges and Future Directions

Despite significant progress in understanding the genetic basis of neuroimmunological disorders, several challenges remain. The complex genetic architecture of these disorders, involving multiple genes and gene-environment interactions, makes it difficult to fully explain disease susceptibility. Further research is needed to identify rare variants with larger effects and to understand how genetic variants interact with environmental factors. Large-scale collaborative efforts, involving the collection of genetic data from diverse populations, are essential for identifying additional susceptibility loci and for replicating findings across different populations. Integrating genetic data with other types of data, such as epigenetic data, transcriptomic data, and clinical data, will be crucial for developing a more comprehensive understanding of disease pathogenesis. Studies on the genetic basis of response to therapies are also crucial for personalized medicine. Finally, functional studies are needed to determine the precise mechanisms by which specific genetic variants contribute to disease risk. By addressing these challenges, we can further advance our understanding of the genetic basis of neuroimmunological disorders and translate these findings into improved diagnostic and therapeutic strategies. Recently, studies have also started to look at the role of gut microbiome in the development of these diseases [10]. This opens another avenue for research and potential therapeutic interventions.

Conclusion

The genetic basis of neuroimmunological disorders is complex, involving both common and rare variants that contribute to disease susceptibility. GWAS, candidate gene studies, and NGS approaches have identified numerous susceptibility loci and have provided valuable insights into disease mechanisms. Future research, focusing on identifying rare variants, gene-environment interactions, and integrating different types of data, will further enhance our understanding of these disorders and pave the way for improved diagnostic and therapeutic strategies.

1. Matysiak A, Roess A (2017).. Journal of tropical medicine 2017.

听听听听听听听听听听听听听 , ,

2. Ribeiro B, Hartley S, Nerlich B, Jaspal R (2018). . Social Science & Medicine 200:137-144.

听听听听听听听听听听听听听聽 , ,

3. Asad H, Carpenter D O (2018). . Reviews on environmental health 33(1)31-42.

, ,

4. Duffin J (2021). . University of Toronto Press.
5. Lavuri R. (2021). . International Journal of Emerging Markets.

听听听听听听听听听听听听听 , Crossref

6. W B Matthews, D A Howell, R D Hughes (1970) . J Neurol Neurosurg Psychiatry 33:330-7.

聽聽聽聽聽聽聽聽聽聽 聽聽, , Crossref

7. Kelly G Gwathmey, A Gordon Smith (2020) . Neurol Clin 38:711-735.

聽聽聽聽聽聽聽聽 聽聽聽聽聽, Crossref

8. Yusuf A Rajabally, Mark Stettner, Bernd C Kieseier, Hans-Peter Hartung, Rayaz A Malik (2017) . Nat Rev Neurol 3:599-611听听听听听听听听听听听听听聽

, , Crossref

9. Juli谩n Benito L, Alex J M (2005) .Clin Neuropharmacol 28:150-1

聽聽聽聽 聽聽聽聽聽聽聽聽聽聽, , Crossref

10. Jean-Michel V, Laurent M, Philippe C, Jean-Marc B, Antonino U, et al. (2020) . J Neuropathol Exp Neurol 79:247-255.

听听听听听听听听听听听听听 , , Crossref